Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04910347

A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma Clinical Trial

Official title:
A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Clinical Trial Summary

The clinical efficacy of nivolumab for locally advanced nasopharyngeal carcinoma patients with residual disease after standard chemoradiotherapy is not known. In this study, we aim to investigate the role of nivolumab in locally advanced NPC after chemoradiotherapy the safety profile and antitumor activity of the anti-programmed death 1 (PD-1) receptor monoclonal antibody, nivolumab after in patients with advanced nasopharyngeal carcinoma

Clinical Trial Description

Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks. As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04910347
Study type Interventional
Source Yonsei University
Contact Hye Ryun Kim
Phone +82-2228-0880
Email nobelg@yuhs.ac
Status Not yet recruiting
Phase Phase 2
Start date June 2021
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05062005 - ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma Phase 3
Completed NCT01462474 - Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 1
Recruiting NCT03574324 - TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Phase 3
Recruiting NCT05860868 - Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma Phase 3
Recruiting NCT05397769 - Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. Phase 2
Not yet recruiting NCT05892354 - Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy N/A
Recruiting NCT03604965 - GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Phase 3
Recruiting NCT03015727 - Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Phase 3
Recruiting NCT05503914 - Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma N/A